Keyphrases
Aberrations
50%
ATRX mutation
14%
B Cells
12%
Breast Cancer
50%
Cancer Dissemination
12%
Chemotherapy
12%
Chemotherapy Resistance
12%
Combination Strategy
12%
Complete Remission
12%
Complete Response
25%
Donor Nephrectomy
12%
Donor Organs
12%
Donor-derived
12%
Effective Treatment
12%
Exon Deletion
21%
High-risk Neuroblastoma
12%
Immune Checkpoint
12%
Immunomodulatory
25%
Immunosuppression
12%
Immunotherapeutics
12%
Immunotherapy Efficacy
12%
Integrative Analysis
50%
Interaction Analysis
12%
Missense
14%
Multiorgan Donor
50%
Mutational Spectrum
50%
Natural Killer Cells
12%
Nectin-2
50%
Neuroblastoma
100%
NKT Cells
12%
Organ Donor
12%
Patient Characteristics
50%
PD-1 Blockade
12%
Pediatric Patients
12%
Poor Survival
12%
Post-chemotherapy
12%
Programmed Death-ligand 1 (PD-L1)
12%
Promising Target
12%
Reduced Cytotoxicity
12%
Relapse Prevention
12%
Single-cell RNA Sequencing (scRNA-seq)
50%
Survival Rate
12%
Syngeneic Model
12%
T Cells
12%
TIGIT
50%
Transplant Recipients
50%
Transplantation
12%
Treatment Options
12%
Tumor
12%
Tumor Characteristics
50%
Medicine and Dentistry
B Cell
10%
Breast Cancer
50%
Cell Line
6%
Chemotherapy
30%
Cytotoxicity
10%
Disease
10%
Ganglioneuroblastoma
100%
Helicase
6%
Immunity
10%
Immunosuppressive Drug
10%
Immunosuppressive Treatment
10%
Immunotherapy
50%
Natural Killer Cell
10%
Natural Killer Cell
10%
Neoplasm
60%
Nephrectomy
10%
Organ Donor
20%
Pediatrics Patient
10%
Point Mutation
6%
Programmed Death-Ligand 1
20%
RNA Sequence
50%
Side Effect
10%
Solid Malignant Neoplasm
6%
Survival Rate
10%
T Cell
20%
Transplantation
50%
Immunology and Microbiology
B Cell
16%
Cytotoxicity
16%
Immunity
16%
Immunosuppressive Drug
16%
Immunotherapy
50%
Myeloid
16%
Natural Killer Cell
16%
Natural Killer T Cell
16%
Programmed Death-Ligand 1
33%
RNA Sequence
50%
Survival Rate
16%
Syngenic
16%
T Cell
16%
